Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
S L Villegas, S Darb-Esfahani, G Von Minckwitz, Jens Huober, K Weber, F Marmé, J Furlanetto, C Schem, B M Pfitzner, B Lederer, K Engels, S Kümmel, V Müller, K Mehta, C Denkert & S Loibl
Our study demonstrates a measurable nuclear expression of Cyclin D1 in post-neoadjuvant residual tumor tissue of HR-positive BC. Cyclin D1 expression was not prognostic for DFS after NACT. Our results and defined cut-off suggest that the marker can be used to stratify tumors according to protein expression levels. Based on this, a prospective evaluation is currently performed in the ongoing Penelope-B trial.
|citation||Villegas S L, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marmé F, Furlanetto J, Schem C, Pfitzner B M, Lederer B, Engels K, Kümmel S, Müller V, Mehta K, Denkert C, Loibl S. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2017; 168:179-187.|
|type||journal paper/review (English)|
|date of publishing||25-11-2017|
|journal title||Breast Cancer Res Treat (168/1)|